Arthneeti

Neuland Laboratories Q1 FY27 Share Price & Earnings Call Analysis

₹19,700.00+2.18% today
Market cap
₹25,275 Cr
P/E
50.78
ROE
21.25%
PEG
1.70
Price to sales
10.65
Debt to equity
0.16
52W high / low
₹23,995 / ₹11,555
Sales growth (5Y)
16.64%
EBITDA margin
32.17%
Net profit margin
17.85%
Promoter holding
32.26%
Sales (last year)
₹2,372 Cr

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Guidance scorecard · Q1 FY27 call

What Neuland Laboratories Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

Revenue10–20%MarginsDown 0–2%CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ4 FY26 call

10–20%
  • Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management.
  • FY26 revenue reached INR 2,000 crores, up from INR 1,500+ crores in FY24, reflecting meaningful growth after a volatile FY25.
  • Growth is expected to remain lumpy and volatile in the short to medium term due to the nature of the business and newer high-value molecules.
  • Long-term growth is anchored by commercial and near-commercial molecules, with a strong pipeline and increasing engagement with big pharma.
  • Investments in large-scale peptide commercial facilities and an upgraded R&D center aim to expand capacity and technical capabilities, supporting sustainable growth.

2 more points from Neuland Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Full Q4 FY26 analysis

MarginsQ4 FY26 call

Down 0–2%

See what Neuland Laboratories Ltd said on margins — free account, 30 seconds.

Full Q4 FY26 analysis

CapexQ4 FY26 call

Planned
  • Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments.
  • Capex outflow for FY26 was INR 397.1 crores, executed with discipline aligned with strategic priorities emphasizing returns and capability building.
  • Investments include building a large-scale peptide commercial facility to expand capabilities in peptide APIs and fragments.
  • New R&D center for supporting complex programs, enhancing scientific depth, collaboration, and scale from early development to commercialization.
  • Capital allocation mindset is evolving to support larger annual capex (hundreds to INR 1,000 crores) for scaling production and engaging big pharma clients.

2 more points from Neuland Laboratories Ltd's call on capex

Create a free account to keep reading this call

Full Q4 FY26 analysis

FundraisingQ4 FY26 call

See what Neuland Laboratories Ltd said on fundraising — free account, 30 seconds.

Full Q4 FY26 analysis

Order bookQ4 FY26 call

  • Management indicates "visibility for projects" especially for the new peptide facility expected to be operational by July, suggesting a healthy pipeline.
  • Early-stage projects for the peptide facility are near commercial, with project visibility but not yet firm contracts.
  • The business development focus is on attracting high-quality, sustainable growth opportunities and larger projects.

2 more points from Neuland Laboratories Ltd's call on the order book

Create a free account to keep reading this call

Full Q4 FY26 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Neuland Laboratories Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Neuland Laboratories Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Neuland Laboratories Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Neuland Laboratories Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +407363418393385440311398328293514440776
Expenses +287266280272278316249311277258359363469
Operating Profit120971371211071236287513415677307
OPM %29%27%33%31%28%28%20%22%16%12%30%18%40%
Other Income +8232525460782812
Interest4244431225577
Depreciation13141515161616161720232425
Profit before tax110831221049213049128391812954287
Tax %23%26%27%22%27%25%34%20%29%21%25%26%26%
Net Profit +8562898168983310228149741213
EPS in Rs65.8948.2369.5663.4452.6676.2825.6079.1821.6810.8375.4931.62165.76

Financials of Neuland Laboratories Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +4695105795276677639379511,1911,5591,4772,023
Expenses +4024304724776086617908079181,0961,1461,448
Operating Profit67801065158102147144273463331574
OPM %14%16%18%10%9%13%16%15%23%30%22%28%
Other Income +0214341609129030
Interest27242119162218141314824
Depreciation151619222631404953606692
Profit before tax25426714205310582216401346489
Tax %36%36%30%13%19%69%23%22%24%25%25%26%
Net Profit +1627471216168164164300260364
EPS in Rs17.9630.7552.7413.5712.8112.6362.8549.74127.45233.89202.74283.71
Dividend Payout %8%7%0%0%0%16%8%10%8%6%6%12%

Financials of Neuland Laboratories Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital99991313131313131313
Reserves1521785375496866977748289811,2701,5121,862
Borrowings +18818219231923126418224112895157301
Other Liabilities +162155148194200257356302457454498754
Total Liabilities5125248861,0711,1301,2311,3251,3831,5801,8332,1802,930
Fixed Assets +1231394664755426537167677588249551,178
CWIP414020126104241720414648210
Investments77888874111092
Other Assets +3403373934634765475855927819621,0681,541
Total Assets5125248861,0711,1301,2311,3251,3831,5801,8332,1802,930

Financials of Neuland Laboratories Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +13453911705718960237261317347
Cash from Investing Activity +-14-20-42-116-77-49-84-95-61-150-298-424
Cash from Financing Activity +1-24-010512-5-11438-136-692521
Net Cash Flow01-4-053-93404244-56
Free Cash Flow-126-2-1217984-37173119112-50
CFO/OP33%70%52%28%128%61%132%56%103%81%119%78%

Financials of Neuland Laboratories Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1008511413490918590111877898
Inventory Days170182186266191209205227211220238247
Days Payable167121118189118110126100129121156130
Cash Conversion Cycle103147182211162190164216193187160214
Working Capital Days11264438138137607481887675
ROCE %16%18%16%4%4%8%11%10%21%33%19%27%

Guidance history

How Neuland Laboratories Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q4 FY26 call →10–20%Down 0–2%Planned——
Q3 FY26 call →20–40%FlatPlanned——
Q2 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

78out of 100

Momentum score · price trend

78 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+21.9%75%
Last 6 months+31.3%82%
Last 3 months+3.5%73%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Neuland Laboratories Ltd: 0.4 × 75 + 0.4 × 82 + 0.2 × 73 = 78.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Neuland Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Accretion Pharmaceuticals Ltd (Q2 FY27)

    25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sigachi Industries Ltd (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

  • Advanced Enzyme Technologies Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym

  • IOL Chemicals (Q2 FY27)

    Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd